Loading…
Loading…
See exactly how IBB's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for IBB and 80,000+ other tickers.
The iShares Biotechnology ETF (IBB) is designed to mirror the investment performance of a specific market index. This index comprises publicly traded stocks from companies operating within the U.S. biotechnology sector.
Biotech stocks are consolidating after a breakout, with bullish insider Wall Street sentiment. AbCellera Biologics and Alpha Cognition stand out for insider buying, revenue growth, and high Seeking Alpha Quant Ratings. ABCL's Phase 2 efficacy readout for ABCL635 in Q3 and ACOG's Zunveyl sales ramp are key catalysts. Both have substantial upside per analyst targets.
IBB delivered 44% returns in one year but swung 40% lower at its worst. IXJ grew steadily with half the volatility and a 1.5% dividend yield.
Asian stocks rallied on Wednesday as investors returned to semiconductor shares after a bruising sell-off, taking their cue from a Wall Street rebound even as Brent crude pushed further above $91 a barrel. MSCI's Asia-Pacific gauge outside Japan gained 1.2%, while South Korea's Kospi surged more than 6% and Japan's Nikkei 225 climbed 1.9%.
I initiate Buy ratings on SPDR S&P Biotech ETF and iShares Biotechnology ETF for 2026–2027, favoring XBI for higher upside. Biotech's rally reflects improving fundamentals: robust M&A, positive clinical data, improved financing, and more quantifiable policy risk, not indiscriminate multiple expansion. MFN drug-pricing risk is narrower than feared, with emerging policies fragmented by payer, product, geography, and voluntary manufacturer participation.
I identify dividend stocks and REITs that could protect investors from AI bubble risks, geopolitics, and inflation while generating attractive income. My "ALLKA Dividend Rating" model separates quality dividend opportunities from yield traps by analyzing dividend sustainability, growth prospects, and valuation. The article explores three dividend strategies, "High-Yield Defensive," "Balanced Income," and "Pure Growth," designed for goals ranging from high yield to dividend growth.